We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Pushes Back Review of Incyte’s JAK Inhibitor for GVHD
FDA Pushes Back Review of Incyte’s JAK Inhibitor for GVHD
The FDA has extended its review of Incyte’s Janus kinase (JAK) inhibitor Jakafi (ruxolitinib) for treating patients with steroid-refractory chronic graft-versus-host disease (GVHD).